BioMotiv, LLC
https://www.biomotiv.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioMotiv, LLC
Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.
Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says
Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.
Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals